Quick Summary
- Pfizer and Astellas received FDA approval for PADCEV (enfortumab vedotin) combined with Keytruda (pembrolizumab) as the first perioperative treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer a major breakthrough for an underserved patient population.
- Phase 3 EV-303 trial results showed a 60% reduction in recurrence or death risk and a 50% reduction in mortality risk compared to surgery alone, with 2-year survival rates of 79.7% versus 63.1%.
- The therapy combines an antibody-drug conjugate (PADCEV targets Nectin-4 on cancer cells) with an immune checkpoint inhibitor (Keytruda), leveraging both direct tumor killing and immune system activation.
Pfizer Inc. and Astellas Pharma Inc. announced FDA approval for PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for muscle-invasive bladder cancer patients ineligible for cisplatin, marking a significant milestone in oncology treatment. The approval comes after unprecedented clinical trial results demonstrated substantial improvements in patient survival outcomes.
A Game-Changing Approval for Underserved Patients
Muscle-invasive bladder cancer presents a critical healthcare challenge, particularly for patients unable to tolerate cisplatin-based chemotherapy. Approximately half of patients with muscle-invasive bladder cancer experience recurrence even after bladder removal surgery, and many are ineligible to receive cisplatin. This new therapeutic option addresses a long-standing treatment gap for this vulnerable population.
The FDA approved the perioperative treatment regimen months earlier than anticipated, positioning it as a potential new standard of care. The accelerated timeline reflects the significance of the clinical evidence supporting the combination therapy.
Phase 3 EV-303 Trial Results: Unprecedented Efficacy
The approval is grounded in compelling data from the Phase 3 EV-303 trial, also known as KEYNOTE-905, which evaluated the combination therapy in patients with previously untreated muscle-invasive bladder cancer who either declined or were ineligible for cisplatin-based chemotherapy. The trial design was unique in evaluating perioperative treatment administration of medications both before and after surgical bladder removal.
Primary Endpoint: Event-Free Survival
The primary endpoint of event-free survival showed a 60% reduction in the risk of disease recurrence, progression or death with perioperative PADCEV plus pembrolizumab compared to surgery alone. The probability of remaining event-free was 74.7% for patients who received the combination and 39.4% for patients treated with surgery only.
Secondary Endpoint: Overall Survival
Perhaps most notably, the combination resulted in a 50% reduction in the risk of death compared to surgery alone. The probability of survival at two years was 79.7% for patients receiving the combination relative to 63.1% for those treated with surgery only.
Read More: U.S. FDA Approves PADCEV® and KEYTRUDA® Combo for Patients with Bladder Cancer
Understanding the Treatment Combination
PADCEV represents a novel class of oncology drug called an antibody-drug conjugate, or ADC. This targeted approach uses antibodies to deliver cancer-killing agents directly to tumor cells. PADCEV is a Nectin-4-directed antibody-drug conjugate that specifically targets a protein found on bladder cancer cells. Keytruda, developed by Merck, is a PD-1 immune checkpoint inhibitor that works by unleashing the body’s immune system to fight cancer.
The combination leverages two complementary mechanisms: direct tumor cell killing through the antibody-drug conjugate and immune activation through checkpoint inhibition, creating a synergistic therapeutic effect.
Clinical Implications and Practice-Changing Potential
Experts in genitourinary oncology recognize the significance of this approval. The trial evidence demonstrates that this combination therapy represents a meaningful advance for a patient population that has lacked effective treatment options for decades. The approval positions PADCEV plus pembrolizumab as a potential new standard of care for cisplatin-ineligible patients with muscle-invasive bladder cancer.
The perioperative treatment model administering therapy both before and after curative surgery introduces a new paradigm for bladder cancer management. This approach aims to address micrometastatic disease that may have already spread before surgery while also potentially reducing post-surgical recurrence.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
A New Era for Bladder Cancer Treatment
The approval of PADCEV plus Keytruda represents a watershed moment in bladder cancer care. For patients ineligible for cisplatin, a population that has historically faced limited treatment options beyond surgery, this combination offers the first FDA-approved perioperative regimen demonstrating meaningful survival advantages. With a 50% reduction in mortality risk and dramatic improvements in event-free survival, this therapeutic approach has the potential to transform outcomes for thousands of patients annually.
As physicians incorporate this new treatment into clinical practice and companies discuss expanded indications with regulatory agencies, muscle-invasive bladder cancer patients and their families have new reason for hope. The results from EV-303 may indeed reshape the treatment landscape and usher in a new standard of care for this serious disease.
Last Modified:
